Compound useful for the treatment of degenerative and inflammatory diseases
A compound is disclosed that has a formula represented by the following: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
1. A method for the treatment of an inflammatory condition selected from Crohn's disease and colitis, or a proliferative disease selected from psoriasis, said method comprising administering a therapeutically effective amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , comprising the administration of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of said compound, or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 , wherein the inflammatory condition is Crohn's disease.
4. The method according to claim 1 , wherein the inflammatory condition is colitis.
5. The method according to claim 1 , wherein the method is for the treatment of psoriasis.
6. The method according to claim 2 , wherein the inflammatory condition is Crohn's disease.
7. The method according to claim 2 , wherein the inflammatory condition is colitis.
8. The method according to claim 2 , wherein the method is for the treatment of psoriasis.
9. The method according to claim 1 , wherein said compound is administered in combination with a further therapeutic agent.
10. The method according to claim 2 , wherein said pharmaceutical composition is administered in combination with a further therapeutic agent.
11. The method according to claim 9 , wherein said further therapeutic agent is an agent for the treatment of Crohn's disease.
12. The method according to claim 9 , wherein said further therapeutic agent is an agent for the treatment of colitis.
13. The method according to claim 9 , wherein said further therapeutic agent is an agent for the treatment of psoriasis.
14. The method according to claim 10 , wherein said further therapeutic agent is an agent for the treatment of Crohn's disease.
15. The method according to claim 10 , wherein said further therapeutic agent is an agent for the treatment of colitis.
16. The method according to claim 10 , wherein said further therapeutic agent is an agent for the treatment of psoriasis.
17. The method according to claim 11 , wherein the further therapeutic agent is an agent selected from glucocorticoids, synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.
18. The method according to claim 17 , wherein the further therapeutic agent is selected from prednisone, budesonide, methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporine, infliximab, adalimumab, rituximab, and abatacept.
19. The method according to claim 12 , wherein the further therapeutic agent is an agent selected from glucocorticoids, synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.
20. The method according to claim 19 , wherein the further therapeutic agent is selected from prednisone, budesonide, methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporine, infliximab, adalimumab, rituximab, and abatacept.
21. The method according to claim 13 , wherein the further therapeutic agent is selected from topical agents selected from coal tar, dithranol, corticosteroids, vitamin D 3 analogues, and retinoids; and systemic agents selected from synthetic disease modifying, immunomodulatory agents, and biological disease modifying, immunomodulatory agents.
22. The method according to claim 21 , wherein the further therapeutic agent is selected from methotrexate, cyclosporine, retinoids, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, fumaric acid esters, and ustekinumab.